CTLT - Catalent, Inc.

QQQ $ 468.86 $ 0.00 (0 %)

DIA $ 409.73 $ 1.01 (0.25 %)

SPY $ 554.79 $ 5.63 (1.03 %)

TLT $ 100.61 $ -0.08 (-0.08 %)

GLD $ 232.25 $ -0.37 (-0.16 %)

Previous Close

$ 59.63

Open

Bid

$ 59.58 x 100

Ask

-- x --

Day's Range

-- - --

52 Week Range

$ 31.80 - $ 61.20

Volume

1,316,177

Average Volume

Market Cap

21.61B

Beta (5Y Monthly)

$ 1.26

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	09-06-2024	06-30-2024	10-K
2	05-08-2024	03-31-2024	10-Q
3	02-14-2024	12-31-2023	10-Q
4	12-08-2023	06-30-2023	10-K
5	12-08-2023	09-30-2023	10-Q
6	06-12-2023	03-31-2023	10-Q
7	02-07-2023	12-31-2022	10-Q
8	11-01-2022	09-30-2022	10-Q
9	08-29-2022	06-30-2022	10-K
10	05-03-2022	03-31-2022	10-Q
11	02-01-2022	12-31-2021	10-Q
12	11-02-2021	09-30-2021	10-Q
13	08-30-2021	06-30-2021	10-K
14	05-04-2021	03-31-2021	10-Q
15	02-02-2021	12-31-2020	10-Q
16	11-03-2020	09-30-2020	10-Q
17	08-31-2020	06-30-2020	10-K
18	05-05-2020	03-31-2020	10-Q
19	02-03-2020	12-31-2019	10-Q
20	11-05-2019	09-30-2019	10-Q
21	08-27-2019	06-30-2019	10-K
22	05-07-2019	03-31-2019	10-Q
23	02-05-2019	12-31-2018	10-Q
24	11-06-2018	09-30-2018	10-Q
25	08-28-2018	06-30-2018	10-K
26	05-01-2018	03-31-2018	10-Q
27	02-05-2018	12-31-2017	10-Q
28	11-06-2017	09-30-2017	10-Q
29	08-28-2017	06-30-2017	10-K
30	05-04-2017	03-31-2017	10-Q
31	02-06-2017	12-31-2016	10-Q
32	11-07-2016	09-30-2016	10-Q
33	08-29-2016	06-30-2016	10-K
34	05-04-2016	03-31-2016	10-Q
35	02-09-2016	12-31-2015	10-Q
36	11-03-2015	09-30-2015	10-Q
37	09-02-2015	06-30-2015	10-K
38	05-05-2015	03-31-2015	10-Q
39	02-12-2015	12-31-2014	10-Q
40	11-14-2014	09-30-2014	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

William Blair Reiterates Market Perform on...
09/03/2024 14:54:20

William Blair analyst Max Smock reiterates Catalent (NYSE:CTLT) with a Market Perform.

Catalent Q4 2024 Adj. EPS $0.65 Beats $0.4...
08/29/2024 11:45:10

Lilly Executive Says Concord Manufacturing...
08/08/2024 14:52:15

Conference Call

Novo Nordisk CFO Said In Active Dialogue W...
08/07/2024 11:41:07

Catalent Completes $25M Upgrade To Schornd...
07/16/2024 06:29:42

The expansion increases the site's footprint by 32,000 square feet (3,000 square meters), adding storage and handling of cl...

RBC Capital Reiterates Sector Perform on C...
07/11/2024 15:00:20

RBC Capital analyst Sean Dodge reiterates Catalent (NYSE:CTLT) with a Sector Perform and maintains $63.5 price target.

Barclays Maintains Equal-Weight on Catalen...
06/28/2024 15:43:01

Barclays analyst Luke Sergott maintains Catalent (NYSE:CTLT) with a Equal-Weight and raises the price target from $47 to $63.

sareptas-expanded-approval-unlikely-to-influence-novo-holdings-acquisition-of-catalent-but-provides-investor-protection-amid-uncertainty

Sarepta's Expanded Approval Unlikely To In...
06/21/2024 17:52:17

Catalent shares rise after Sarepta Therapeutics' Elevidys expanded approval. Despite uncertainties, Catalent's risk/rew...

Catalent Stockholders Approve Acquisition ...
05/29/2024 13:08:31

hedge-funds-tweak-portfolios-in-q1-marvell-td-synnex-aes-get-more-love-as-focus-shifts-to-ai

Hedge Funds Tweak Portfolios In Q1: Marvel...
05/24/2024 16:19:57

Hedge funds are looking for high-return opportunities beyond the mega-cap tech giants preferring to focus on cyclical sectors a...

Catalent Q3 EPS $(0.06) Misses $0.21 Estim...
05/08/2024 22:25:21

Catalent (NYSE:CTLT) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $0.21 by 128...

Siren Biotechnology And Catalent Partner T...
05/08/2024 15:05:04

demand-soars-for-novo-nordisks-weight-loss-drug-wegovy-despite-supply-constraints-and-eli-lilly-competition

Demand Soars For Novo Nordisk's Weight-Los...
05/02/2024 09:48:44

The Danish pharmaceutical company is now shipping more introductory doses of Wegovy to the U.S., as it grapples with supply con...

novo-nordisks-dominance-in-obesity--diabetes-drug-market-backed-by-strong-pipeline-analyst-gives-outperform-rating

Novo Nordisk's Dominance In Obesity & Diab...
04/12/2024 17:22:39

BMO's coverage of Novo Nordisk, spotlighting its groundbreaking advancements in weight loss and diabetes drugs. Analysts fo...

Beyond The Numbers: 6 Analysts Discuss Cat...
04/04/2024 15:01:07

Stephens & Co. Reiterates Equal-Weight on ...
04/04/2024 14:26:35

Stephens & Co. analyst Jacob Johnson reiterates Catalent (NYSE:CTLT) with a Equal-Weight and maintains $63.5 price target.

Invenra To Collaborate With Catalent To Co...
04/02/2024 17:59:04

https://www.businesswire.com/news/home/20240402320363/en/

novo-nordisk-sets-timeframe-for-its-next-gen-experimental-obesity-drug

Novo Nordisk Sets Timeframe For Its Next-G...
03/08/2024 16:12:01

"Novo Nordisk's optimism soars with promising early trial data for amycretin, an experimental weight loss pill. Expect ...

Novo Nordisk CFO Says If Catalent Deal Doe...
03/07/2024 16:01:02

Novo Nordisk CFO Says If Catalent Deal Doe...
03/07/2024 15:47:42

- Conf Call